Celgene-CELG Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celgene-CELG

CELG 108.24

0.0%

Nov 22 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (211)	12/10/1998 10:33:00 PM
From: Miljenko Zuanic	Read Replies (1) of 804

Thanks Peter. <<$4-5m this year, $50m next year. Drug cost for cancer patients is $18k per year, so less than 3k cancer patients projected for next year - seems conservative to me. >> Regards the pts # for 99 projection is way to conservative. Regards the therapy costs per pts numbers are bit to aggressive. I will project therapy costs (cancer pts variation) at 7-10K , while pts # at 10-12 K for 99 [ 2-3 K MDs (STEPS members) x 4-5 pts/MD). Consequently, T revenue at 70-100 MM (at healthy margin of 85-90%) and net T profit (after max 10% royalty to ENMD???) at 50-70 MM. Not bad for ~180 MM capitalization company. :) Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next